Summary
MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients
MannKind Corporation delivered strong Q3 '25 results, beating EPS and revenue estimates, and shares have responded positively. The FDA accepted the supplemental New Drug Application for the FUROSCIX ReadyFlow Autoinjector, offering rapid furosemide delivery for CHF and CKD patients. I see a substantial TAM, estimating 670,000 to 1.34 million potential U.S. heart failure patients for ReadyFlow, with significant revenue implications.
MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript
MannKind Corporation ( MNKD ) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease November 10, 2025 9:00 AM EST Company Participants Michael Castagna - CEO & Director Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, and welcome to MannKind Corporation's investor call to discuss a clinical trial update.
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
MannKind Corporation (MNKD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has MannKind Corporation ever had a stock split?
MannKind Corporation Profile
| Biotechnology Industry | Healthcare Sector | Michael E. Castagna CEO | NASDAQ (NMS) Exchange | 56400P706 CUSIP |
| US Country | 403 Employees | - Last Dividend | 3 Mar 2017 Last Split | 28 Jul 2004 IPO Date |
Overview
MannKind Corporation is a pioneering biopharmaceutical company with a primary focus on creating and commercializing inhaled therapeutic products aimed at treating endocrine and orphan lung diseases primarily within the United States. The company has carved a niche in the healthcare sector by offering innovative solutions like Afrezza, an inhaled insulin, and the V-Go wearable insulin delivery device for adults with diabetes, showcasing its commitment to improving the quality of life for patients with chronic conditions. Beyond its current offerings, MannKind is engaged in the development of an exciting pipeline of products intended for the treatment of a variety of serious pulmonary conditions. Through strategic collaborations and agreements with companies such as United Therapeutics Corporation, Vertice Pharma, and Cipla Ltd., as well as partnerships for the commercialization of its products in international markets like Brazil and India, MannKind Corporation continues to expand its global footprint and impact. Founded in 1991 and based in Danbury, Connecticut, the company is a testament to the enduring pursuit of innovation in the healthcare industry.
Products and Services
- Afrezza
An innovative inhaled insulin product designed to improve glycemic control in adults suffering from diabetes. This product exemplifies MannKind's leadership in developing inhaled therapeutic solutions for chronic diseases.
- V-Go Wearable Insulin Delivery Device
A cutting-edge solution for adults with diabetes, providing a continuous subcutaneous infusion of insulin. This device highlights MannKind's dedication to improving diabetes management through innovative technology.
- Tyvaso DPI (Treprostinil)
An inhalation powder in development for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. This collaboration with United Therapeutics Corporation showcases MannKind's focus on addressing severe pulmonary diseases through advanced inhalation technologies.
- MNKD-101
A nebulized formulation of clofazimine under development for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, demonstrating MannKind's commitment to combating complex pulmonary conditions.
- MNKD-201
A dry-powder formulation of nintedanib being developed for the treatment of idiopathic pulmonary fibrosis (IPF), highlighting MannKind's innovative approach to addressing fibrotic lung diseases.
- Collaborations and Agreements
MannKind Corporation has established essential collaborations and licensing agreements aimed at the development, regulatory approval, and commercialization of its products. Notable partnerships include a co-promotion agreement with Vertice Pharma for Thyquidity and collaborations with Thirona, Biomm S.A., and Cipla Ltd. for the global distribution and marketing of Afrezza. These strategic alliances underscore MannKind's global outreach and its commitment to making its life-changing therapies available worldwide.
Contact Information
